Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin A  COVID-19 treatment studies for Vitamin A  C19 studies: Vitamin A  Vitamin A   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 26% unadjusted Improvement Relative Risk c19early.org/va Doocy et al. NCT04568499 Vitamin A LATE TREATMENT Favors vitamin A Favors control
Clinical progression and outcomes of patients hospitalized with COVID-19 in humanitarian settings: A prospective cohort study in South Sudan and Eastern Democratic Republic of the Congo
Doocy et al., PLOS Global Public Health, doi:10.1371/journal.pgph.0000924, NCT04568499 (history)
19 Oct 2022    Source   PDF   Share   Tweet
Prospective study of 144 hospitalized COVID-19 patients in the DRC and South Sudan, showing no significant difference with vitamin A treatment in unadjusted results with only 8 patients receiving vitamin A.
risk of death, 26.1% lower, RR 0.74, p = 1.00, treatment 1 of 8 (12.5%), control 23 of 136 (16.9%), NNT 23, unadjusted.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
Doocy et al., 19 Oct 2022, prospective, multiple countries, peer-reviewed, 6 authors, study period December 2020 - June 2021, trial NCT04568499 (history).
Contact: doocy1@jhu.edu.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin AAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit